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Summary 
Implementation of methicillin-resistant Staphylococcus aureus (MRSA) decolonization 
programs has been increasing and the emergence of mupirocin resistance has been reported. 
However, the patient level risk factors associated with mupirocin resistance are not clear. We 
identified independent predictors of mupirocin resistance in MRSA among Providence Veterans 
Affairs Medical Center patients with MRSA positive culture dates between July 1, 2004 and 
June 30, 2008 using a frequency matched case-control study. Forty cases (mupirocin-resistant) 
were matched on culture date quarter and year to 270 controls (mupirocin susceptible). The 
adjusted conditional logistic regression model identified three significant independent predictors 
associated with mupirocin resistance in MRSA: 1) exposure to mupirocin in the year prior to the 
culture date (odds ratio [OR] 9.84, 95% confidence interval [CI] 2.93-33.09), 2) Pseudomonas 
aeruginosa infection in the year before the culture-related admission (OR 4.85, 95% CI 1.20-
19.61), and 3) cefepime utilization in the year prior to culture (OR 2.80, 95% CI 1.03-7.58). In 
sensitivity analyses, previous mupirocin exposure was associated with low-level (minimum 
inhibitory concentrations [MICs] 8–128 mg/L; 23 cases, 202 controls; OR 6.32, 95% CI 1.58-
25.33) and high-level (MICs ≥256 mg/L; 17 cases, 151 controls; OR 11.18, 95% CI 1.89-66.30) 
mupirocin resistance. To our knowledge, this is the first case-control study to reveal a strong 
association between previous mupirocin exposure and subsequent mupirocin resistance in 
MRSA, with demonstrated robustness in low and high-level mupirocin resistance. Mupirocin 
susceptibility monitoring is critical for facilities instituting decolonization with mupirocin as 
increased utilization may reduce effectiveness through resistance. 
 
Keywords: methicillin-resistant Staphylococcus aureus, mupirocin resistance, risk factors 
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Introduction 
 
Despite the implementation of evidence-based infection control practices, methicillin-resistant 
Staphylococcus aureus (MRSA) infection and colonization rates continue to increase, 
contributing to escalating healthcare costs.1-4 Decolonization regimens, including the eradication 
of MRSA carriage with topical antimicrobial and antiseptic agents, have been used variably in 
the clinical setting.4, 5 Mupirocin has been the mainstay of decolonization therapy as it is the only 
topical antibiotic approved for the eradication of MRSA nares colonization in the United States.6 
However, decolonization with mupirocin remains controversial as eradication appears to be 
short-term, is not achieved in all patients, and does not consistently prevent subsequent 
infections.7-11 
 
Mupirocin resistance emerged shortly after this topical antibiotic was introduced into 
clinical practice, thus affecting the efficacy and effectiveness of mupirocin.8, 9, 12-14 A plasma-
mediated mupA gene appears to be associated with high-level resistance, while low-level 
resistance is associated with chromosomal point mutations.6, 15-17 Data collected from 
susceptibility monitoring can be used to discern the population subgroups at the highest risk for 
mupirocin-resistant MRSA as no common risk factors have been identified from the limited 
research conducted to date.18-21 It was therefore the intent of this study to identify independent 
predictors associated with mupirocin-resistant MRSA among our Veterans Affairs Medical 
Center (VAMC) patients in Providence, Rhode Island, United States. 
 
Methods 
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Study setting and data sources  
 
Routine mupirocin susceptibility testing of MRSA isolates was initiated in June of 2004 at the 
Providence VAMC, a 119-bed hospital with 32 subspecialty clinics. The Infectious Diseases 
Research Laboratory assessed each patient’s first unique MRSA isolate from any culture site 
within a calendar year for mupirocin resistance using E-tests (AB Biodisk, Solna, Sweden) to 
determine minimum inhibitory concentrations (MICs). For these analyses, mupirocin 
susceptibility results were combined with inpatient and outpatient data extractions from 
standardized databases and electronic medical records. This study was reviewed and approved by 
the Institutional Review Boards of the Providence VAMC and University of Rhode Island, and 
the Providence VAMC Research and Development Committee. 
 
Patient population and study design 
 
Our retrospective pharmacoepidemiologic study utilized a case-control design. Adults with 
MRSA positive culture dates between July 1, 2004 and June 30, 2008 were selected for 
inclusion. Amongst this eligible population, we identified two groups of patients, those with 
mupirocin-resistant (cases) and susceptible (controls) isolates. Resistance included both low (8–
128 mg/L) and high-level (≥256 mg/L) MICs as each has been associated with therapy failure.8, 9, 
13, 14, 22 We categorized isolates with MICs less than or equal to 4 mg/L as susceptible and 
selected the first MRSA positive isolate, identified by the earliest culture date during the study 
period, for inclusion. We employed case-base sampling to select controls with susceptible 
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isolates from the source population. Cases were frequency matched with controls on culture date, 
randomly selecting up to 10 controls per case within strata of culture date quarter and year (16 
quarters over four years).   
 
Independent predictors 
 
The potential predictors assessed included patient demographics and comorbid conditions, as 
well as healthcare and antibiotic exposures. We utilized International Classification of Diseases, 
Ninth Edition (ICD-9) diagnosis and procedure codes associated with inpatient admissions and 
outpatient visits to identify patient comorbidities, including site-specific and organism-specific 
infections, in the year prior to admission. As the relevant exposure window for mupirocin 
resistance is not well-defined, we evaluated inpatient admissions and surgeries in two non-
mutually exclusive time periods (90 days and one year) prior to the culture-related admission. 
We manually reviewed all microbiology results from electronic medical records to determine 
whether patients were colonized, infected, or concomitantly colonized and infected with MRSA. 
Antibiotic exposures in the 90 days prior to the culture date (recent past) and in the previous year 
were assessed from inpatient and outpatient prescription records. We evaluated cephalosporins 
by generation (i.e. 1st, 2nd, 3rd, and 4th) separately from other beta-lactams as an association 
between third-generation cephalosporins and low-level mupirocin resistance has been reported.21  
 
Statistical analysis 
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We assessed between-group differences by case-control status using a χ2 or Fisher’s exact test as 
appropriate for categorical covariates and the Mann-Whitney U test for non-normally distributed 
continuous variables. In multivariable modeling, a manual, non-computer generated backward 
elimination approach was implemented to identify independent predictors associated with 
mupirocin resistance.23 Model development was guided by likelihood ratio tests, Wald statistics, 
and parameter coefficients.23 We estimated crude and adjusted odds ratios, including their 
respective 95% confidence intervals, with conditional logistic regression. In sensitivity analyses, 
the predictors we identified in the primary analysis were evaluated separately for low and high-
level mupirocin resistance. All statistical tests were conducted with a two-tailed alpha and all 
analyses were performed using SAS (SAS Institute Inc., Cary, NC, Version 9.1.3).  
 
Results 
 
Among Providence VAMC patients, 40 cases with mupirocin-resistant MRSA isolates were 
identified during the study period. The average number of cases per quarter was three (40 cases 
in 12 quarters). All cases were successfully matched to 270 controls, of the available 369 patients 
with mupirocin susceptible MRSA positive isolates, based on culture date quarter and year. Each 
case had between three and ten matched controls (mean 7). Surgical procedures, chronic skin 
ulcers, and Pseudomonas aeruginosa (P. aeruginosa) infections were more common among 
mupirocin-resistant MRSA cases compared to susceptible controls in the year prior to the 
culture-related admission. No other significant variations in demographics, comorbid conditions, 
and healthcare exposures were observed by case-control status, as illustrated in Tables I and II. 
While antibiotic utilization was assessed in the 90 days before the culture date, univariate 
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likelihood ratio testing identified inpatient and outpatient exposures during the previous year to 
be more significant. Fluoroquinolones were the most commonly prescribed antibiotic class 
among cases and controls, as detailed in Table III. Cases were exposed to mupirocin, 
vancomycin, and cefepime more often than controls.  
 
The adjusted conditional logistic regression model identified three independent predictors 
associated with mupirocin-resistant MRSA, as presented in Table IV. Mupirocin resistance was 
9.84 times more likely among patients exposed to mupirocin in the year prior to the culture date 
compared to those with no such antibiotic exposure. The site of previous mupirocin exposure 
(7/17 nares, 10/17 skin) did not vary by case-control status. Mupirocin exposures occurred in the 
outpatient (5/7 cases, 8/10 controls) and inpatient (4/7 cases, 5/10 controls) settings (includes 
multiple therapy episodes). Among patients exposed in the outpatient setting for nares 
decolonization, 83% (5/6) were treated preoperatively. There were no significant differences in 
length of previous mupirocin exposure by case-control status.  
 
Additionally, previous treatment with cefepime, a fourth-generation cephalosporin, was 
independently associated with mupirocin resistance. The mean length of prior cefepime therapy 
did not differ significantly between cases and controls. MRSA isolates from patients infected 
with P. aeruginosa in the year before the culture-related admission were 4.85 times more likely 
to display mupirocin resistance as compared to cultures from patients without a history of this 
infection type. Sensitivity analyses (Table IV) substantiated previous mupirocin exposure as an 
independent predictor of low-level (23 cases, 202 controls) and high-level (17 cases, 151 
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controls) mupirocin resistance, while the association with previous P. aeruginosa infection was 
only observed in low-level resistance. 
 
Discussion 
 
To our knowledge, this is the first published case-control study to reveal a strong association 
between previous mupirocin exposure and subsequent mupirocin resistance in MRSA, with 
demonstrated robustness in low and high-level mupirocin resistance. While the selective pressure 
of antibiotics intuitively affects the development of resistance and several researchers have 
ecologically attributed increased mupirocin resistance to escalated mupirocin utilization, formal 
analytic comparisons had yet to substantiate this hypothesis at the patient-level.13, 18, 19, 21, 24, 25 In 
a placebo-controlled trial, exposure to mupirocin before randomization was not associated with 
resistance (RR 1.52, 95% CI 0.71-3.27).13 Further, mupirocin therapy was not predictive of 
resistance in a case-control study conducted among patients from the VAMC in Mountain Home, 
Tennessee (OR 1.64, 95% CI 0.77-3.53).18 Despite this finding, rising high-level resistance rates 
at the Mountain Home VAMC coincided with increased facility-level mupirocin use over the 
study period and a decline in resistance was later observed among inpatient non-nares MRSA 
isolates after restrictions were placed on mupirocin prescribing practices.18, 25  
 
In our study, we identified previous P. aeruginosa infections and prior utilization of 
cefepime to be independent predictors of mupirocin resistance, although the reasons for the 
observed associations are less apparent. Mupirocin is an antibiotic produced by the gram-
negative bacteria Pseudomonas fluorescens. As such, Pseudomonas is insensitive to mupirocin 
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resulting from its inherent resistance to the antibiotic it produces.26, 27 The mupA gene, which 
exists in both low and high-level resistance, is unstable and the movement of mupA-mediated 
mupirocin resistance between plasmids exists between bacterial isolates.28-30 It is currently 
unknown if P. aeruginosa is a carrier and potentially harbors the mupA gene complex. P. 
aeruginosa infections among cases did not vary significantly by level of mupirocin resistance, 
and while Pseudomonas was predictive of low-level resistance, the decreased sample size in 
sensitivity analyses likely impacted the lack of association with high-level resistance. No 
differences were discerned by case-control status in P. aeruginosa susceptibility profiles and P. 
aeruginosa infection sites (e.g. skin, urine, sputum). Perhaps the significance of this predictor 
relates to its opportunistic nature, affecting seriously ill patients, rather than the infecting 
organism itself.  
 
Cefepime is a broad-spectrum antibiotic with activity against a number of gram-positive 
and gram-negative organisms.31 Although cefepime is indicated for the treatment of P. 
aeruginosa infections, the overlap between these predictors was not significant (6/31), as 
confirmed by the absence of collinearity and effect modification. We did not observe patterns 
related to prescribing physician or underlying infection responsible for the cefepime exposure 
that would explain the association with mupirocin resistance. In a case-control study conducted 
among patients admitted to the intensive care units of a Korean hospital, antibiotics, other than 
cefepime and topical mupirocin, were identified as predictors of mupirocin-resistant MRSA 
including piperacillin-tazobactam (odds ratio [OR] 13.8, 95% confidence interval [CI] 1.8-
105.0), third-generation cephalosporins (OR 5.0, 95% CI 1.6-15.5), and quinolones (OR 3.4, 
95% CI 1.1-10.7).21 These empiric exposures to antibiotics without MRSA coverage may select 
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for MRSA exhibiting mupirocin resistance. Or, this finding may be the result of combined 
patient-level factors and aggregate comorbidity burden of an underlying group of patients that 
was not detected by the individual covariates assessed. 
 
The findings of this study are limited in several manners. The study sample size was 
small, including 40 cases with mupirocin resistance and 270 matched controls with mupirocin 
susceptible MRSA. While the estimated measures of association may be imprecise, the direction 
of the association is not affected by the small sample size, as evidenced with the consistency of 
the significant crude and multivariable adjusted estimates. Even at the low end of the confidence 
interval, mupirocin resistance is still 2.93 times more likely among those exposed to mupirocin 
in the year prior to culture, representing a clinically relevant increased risk. Another limitation is 
the lack of knowledge regarding the timing of organism acquisition. We were not able to capture 
the length of colonization or infection. As such, antibiotic exposures may have occurred after 
colonization or infection with either mupirocin susceptible or mupirocin-resistant MRSA.  
 
Our study was also limited by the utilization of ICD-9 diagnosis codes for the 
identification of previous infections. The sensitivity and specificity of many organism-specific 
diagnosis codes, including MRSA and Pseudomonas, are not known. These codes may be under-
utilized in comparison to site-specific infection codes. Unobserved covariates have the potential 
to influence the findings of any study through residual confounding. The aim of this study was 
not to provide evidence in support of a causal association between a specific exposure and 
mupirocin resistance necessitating the control of confounding factors in order to observe the true 
association, but rather to identify independent predictors of mupirocin resistance. Our study 
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findings are limited to the population served by the Providence VAMC. Only eight women were 
included in this study (0 cases, 8 controls), limiting the generalizability of the findings.  
 
While few independent predictors of mupirocin resistance have been elucidated to date, 
we demonstrated the utility of mupirocin susceptibility monitoring for the identification of 
patient-level factors associated with resistance. We observed a substantial increased risk of 
mupirocin-resistant MRSA, including both low and high-level resistance, among patients 
previously exposed to mupirocin. An increased likelihood of mupirocin resistance was also noted 
among patients infected with Pseudomonas in the year before admission or treated with cefepime 
in the year prior to culture. Future research directions include substantiating each of these 
independent predictors as risk factors for mupirocin resistance, including the assessment of 
possible mechanisms, causal or otherwise, for these associations in risk factor analyses. 
Forthcoming investigations should also focus on the prognosis of patients with mupirocin 
resistance in terms of clinical outcomes.
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Table I. Demographics and comorbid conditions among patients with mupirocin-resistant (cases) 
or mupirocin susceptible (controls) methicillin-resistant Staphylococcus aureus. 
Covariates Cases 
N = 40 
Controls 
N = 270 
P-value 
Age (years), mean (sd) 75.6 (11.0) 72.0 (13.1) 0.12 
Male gender 40 (100.0) 262 (97.0) 0.60 
Race   
0.96     White 32 (80.0) 217 (80.4) 
    Other/unknowna 8 (20.0) 53 (19.6) 
Comorbid conditions    
    Chronic respiratory diseaseb 21 (52.5) 110 (40.7) 0.16 
    Renal disease 21 (52.5) 115 (42.6) 0.24 
    Diabetes 20 (50.0) 108 (40.0) 0.23 
    Heart failure 18 (45.0)  103 (38.2) 0.41 
    Coronary heart disease 17 (42.5)  125 (46.3) 0.65 
    Cancer 9 (22.5) 68 (25.2) 0.71 
    Dialysis 3   (7.5) 13   (4.8) 0.44 
Infections, previous yearc    
    Pneumoniad 14 (35.0) 62 (23.0) 0.10 
    Chronic skin ulcerd 11 (27.5) 40 (14.8) 0.04 
    Bacteraemiad 4 (10.0) 13   (4.8) 0.25 
    MRSA 3   (7.5) 14   (5.2) 0.47 
    Pseudomonas aeruginosa 5 (12.5) 5   (1.9) <0.01 
Data are no. (%), unless otherwise indicated. sd, standard deviation; MRSA, methicillin-resistant 
Staphylococcus aureus. 
a “Other/unknown” race includes African American, Native Hawaiian/Pacific Islander, and 
unknown. 
b “Chronic respiratory disease” includes chronic bronchitis, asthma, and emphysema. 
c Infection in the year prior to admission. 
d Attributed to any organism.  
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Table II. Healthcare exposures and culture characteristics among patients with mupirocin-
resistant (cases) or mupirocin susceptible (controls) methicillin-resistant Staphylococcus aureus. 
Covariates Cases 
N = 40 
Controls 
N = 270 
P-value 
Inpatient admission    
    Previous 90 days 18 (45.0) 98 (36.3) 0.29 
    Previous year 28 (70.0) 166 (61.5) 0.30 
Surgery     
    During admission 8 (20.0) 58 (21.5) 0.83 
    Previous 90 days 4 (10.0) 16   (5.9) 0.31 
    Previous year 10 (25.0) 32 (11.9) 0.02 
Admitted from home 37 (92.5) 228 (84.4) 0.23 
Devices during admissiona    
    Central catheter 8 (20.0) 32 (11.9) 0.15 
    Urinary catheter 7 (17.5) 37 (13.7) 0.52 
    Mechanical ventilation 3   (7.5) 28 (10.4) 0.78 
Culture site    
    Nares 28 (70.0) 167 (61.9) 0.32  
    Tissue 5 (12.5) 29 (10.7) 0.79  
    Sputum 3   (7.5) 35 (13.0) 0.44 
    Urine 3   (7.5) 11   (4.1) 0.40  
    Blood 1   (2.5) 17   (6.3) 0.49  
    Bone 0  (0.0) 3   (1.1) 1.00  
    Non-specific 0   (0.0) 8   (3.0) 0.60 
Unit on culture dateb   
0.60 
         Emergency  14 (35.0) 94 (34.8) 
         Intensive care  4 (10.0) 43 (15.9) 
         Other 22 (55.0) 133 (49.3) 
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Table II. Healthcare exposures and culture characteristics among patients with mupirocin-
resistant (cases) or mupirocin susceptible (controls) methicillin-resistant Staphylococcus aureus 
(cont). 
Covariates Cases 
N = 40 
Controls 
N = 270 
P-value 
Colonization and/or infectionb   
0.48 
         Colonization 23 (57.5) 145 (53.7) 
         Infection 9 (22.5) 84 (31.1) 
         Colonization and infection 8 (20.0) 41 (15.2) 
Data are no. (%). 
a Devices present during the inpatient admission before the culture date. 
b Two degrees of freedom. 
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Table III. Antibiotic exposures in the previous yeara among patients with mupirocin-resistant 
(cases) or mupirocin susceptible (controls) methicillin-resistant Staphylococcus aureus. 
Antibiotics Cases 
N = 40 
Controls 
N = 270 
P-value 
Aminoglycoside 5 (12.5) 12   (4.4) 0.05 
Beta-lactam 20 (50.0) 119 (44.1) 0.48 
Cephalosporin,  
1st generation 
12 (30.0) 65 (24.1) 0.42 
Cephalosporin,  
2nd generation  
4 (10.0) 18   (6.7) 0.50 
Cephalosporin,  
3rd generation  
10 (25.0) 48 (17.8) 0.27 
Cephalosporin,  
4th generation (cefepime) 
9 (22.5) 22   (8.2) 0.01 
Fluoroquinolone 25 (62.5) 128 (47.4) 0.08 
Lincosamide 2   (5.0) 21   (7.8) 0.75 
Linezolid 2   (5.0) 8   (3.0) 0.62 
Macrolide 7 (17.5) 81 (30.0) 0.10 
Metronidazole 11 (27.5) 53 (19.6) 0.25 
Mupirocin  7 (17.5) 10   (3.7) <0.01 
Sulfamethoxazole/trimethoprim 10 (25.0) 37 (13.7) 0.06 
Vancomycin 18 (45.0) 70 (25.9) 0.01 
Data are no. (%). 
a Exposures in the year before the culture date, at least one dose. 
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Table IV. Predictors of mupirocin resistance in methicillin-resistant Staphylococcus aureus. 
Covariates Crude1  Adjusted2 
Odds 
Ratio 
95% 
Confidence 
Interval 
 
Odds 
Ratio 
95% 
Confidence 
Interval 
 
P-value 
Mupirocin-resistant 
    Cefepimea 3.08      1.28-7.41  2.80 1.03-7.58 0.04 
    Mupirocina 5.02 1.75-14.44  9.84 2.93-33.09 <0.01 
    P. aeruginosa    
    infectionb 
6.60 1.81-24.07 
 
4.85 1.20-19.61 0.03 
Low-level mupirocin-resistant 
    Mupirocina 3.88 1.08-13.92  6.32 1.58-25.33 <0.01 
    P. aeruginosa  
    infectionb 
6.66 1.43-30.96 
 
8.50 1.76-41.11 <0.01 
High-level mupirocin-resistant 
    Mupirocina 6.45 1.33-31.27  11.18 1.89-66.30 <0.01 
1 Estimated from conditional logistic regression.  
2 Estimated from conditional logistic regression, adjusted by age, race, and predictors. 
a Exposures in the year before the culture date, at least one dose. 
b Pseudomonas aeruginosa infection in the year prior to admission. 
 
